Use of firsekibart for acute gouty arthritis in a maintenance hemodialysis patient with multiple high-risk comorbidities: a case report
- 1The First Affiliated Hospital (The First Clinical Medical School) of Guangdong Pharmaceutical University
- 2Nephrology Department, General Hospital of Southern Theater Command
Abstract
Objective: To describe the clinical course of Firsekibart treatment for acute gouty arthritis in a 51-year-old patient receiving maintenance hemodialysis with multiple high-risk comorbidities, focusing on the temporal relationship among dialysis, drug administration and the timing of symptom changes. This report adds to the limited evidence on using Firsekibart, a novel fully human monoclonal antibody targeting IL-1β, in patients receiving maintenance hemodialysis.
Methods: We retrospectively reviewed the patient’s underlying diseases, acute gout manifestations, timing of Firsekibart administration relative to hemodialysis, visual analogue scale (VAS) pain scores, body temperature, and inflammatory markers. The clinical course was interpreted in the context of available clinical evidence on Firsekibart, experience with other IL-1 pathway agents in patients with advanced chronic kidney disease and/or receiving dialysis, and monoclonal antibody pharmacokinetics.
Results: Pain relief was documented 6–7 h after Firsekibart administration, before the first post-dose hemodialysis session; however, tramadol and topical flurbiprofen had been administered within the preceding hour and may have contributed to the observed improvement. No worsening or rebound of pain was observed on the day of dialysis or the following day. No immediate hypersensitivity reaction was observed during the early post-dose period. Follow-up continued through 24 June 2026 (35 days post-dose), no gout flare recurred; however, biliary symptoms and a febrile episode with suspected catheter-related bloodstream infection occurred, with uncertain relationships to Firsekibart.
Conclusion: In this maintenance hemodialysis patient, gout-related pain improved before the first post-dose dialysis session and did not rebound after dialysis. However, this single case, without pre- or post-dialysis Firsekibart concentration measurements, cannot establish causality or determine the effect of hemodialysis on drug exposure.
Related
- Construction and validation of an identification model for frailty in maintenance hemodialysis patients using multiple machine learning algorithms: a cross-sectional study of retrospectively collected data
- Development of a nomogram for identifying prevalent medication discrepancy in maintenance hemodialysis patients: a multicenter cross-sectional study
- Prevalence and factors associated with pulmonary hypertension in patients undergoing maintenance hemodialysis: a systematic review and meta-analysis
- Physiological discordance between clinical examination, bioimpedance spectroscopy, and lung ultrasound in maintenance hemodialysis patients without heart failure
- Effects of Dialysate Calcium Concentration on Bone, Mineral Metabolism, and Vascular Outcomes in Maintenance Hemodialysis: A Systematic Review and Meta-Analysis
BibTeX
@article{chen2026firsekibart,
title = {{Use of firsekibart for acute gouty arthritis in a maintenance hemodialysis patient with multiple high-risk comorbidities: a case report}},
author = {Jiaqi Chen and Ruoyu Tong and Meng Shen and Weidong Zhang and Yuanhang Huang},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1928098},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1928098/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Use of firsekibart for acute gouty arthritis in a maintenance hemodialysis patient with multiple high-risk comorbidities: a case report
AU - Jiaqi Chen
AU - Ruoyu Tong
AU - Meng Shen
AU - Weidong Zhang
AU - Yuanhang Huang
PY - 2026
DA - 2026/10/15
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1928098
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1928098/full
AB - Objective: To describe the clinical course of Firsekibart treatment for acute gouty arthritis in a 51-year-old patient receiving maintenance hemodialysis with multiple high-risk comorbidities, focusing on the temporal relationship among dialysis, drug administration and the timing of symptom changes. This report adds to the limited evidence on using Firsekibart, a novel fully human monoclonal antibody targeting IL-1β, in patients receiving maintenance hemodialysis. Methods: We retrospectively reviewed the patient’s underlying diseases, acute gout manifestations, timing of Firsekibart administration relative to hemodialysis, visual analogue scale (VAS) pain scores, body temperature, and inflammatory markers. The clinical course was interpreted in the context of available clinical evidence on Firsekibart, experience with other IL-1 pathway agents in patients with advanced chronic kidney disease and/or receiving dialysis, and monoclonal antibody pharmacokinetics. Results: Pain relief was documented 6–7 h after Firsekibart administration, before the first post-dose hemodialysis session; however, tramadol and topical flurbiprofen had been administered within the preceding hour and may have contributed to the observed improvement. No worsening or rebound of pain was observed on the day of dialysis or the following day. No immediate hypersensitivity reaction was observed during the early post-dose period. Follow-up continued through 24 June 2026 (35 days post-dose), no gout flare recurred; however, biliary symptoms and a febrile episode with suspected catheter-related bloodstream infection occurred, with uncertain relationships to Firsekibart. Conclusion: In this maintenance hemodialysis patient, gout-related pain improved before the first post-dose dialysis session and did not rebound after dialysis. However, this single case, without pre- or post-dialysis Firsekibart concentration measurements, cannot establish causality or determine the effect of hemodialysis on drug exposure.
SN - 1663-9812
ER -